Non-specific multimodal treatment of solid cancer including surgery, radiotherapy and systemic treatment with cytotoxic chemotherapy and targeted drugs in selected patients have improved oncological outcomes. However resistance, treatment failure and death rates still remain high particularly in advanced disease. Recently, high-throughput next-generation sequencing and arrays-based technologies have revolutionized biomedical research. However, the translation of deep-sequencing data into clinic in the emerging network biology seems to require additional understanding of dynamic complex signaling transduction pathway networks. Here, I discuss the results of the first published studies with deep-sequencing and transcriptomic analysis data of clinical samples from roughly 2400 breast cancer and 1125 medulloblastoma patients. The potential and challenges in how to adopt new genomic discoveries into novel robust biomarkers and cancer targets are also described.
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CANCER ADVANCES AND LIMITATIONS
Despite advances with non-specific therapies (surgery, radiotherapy and cytotoxic chemotherapy) and over the last decade with targeted therapy, incidence and mortality rates are high. Research has moved to biomarkers and cell signaling inhibitors, but with the exception of few drugs including trastuzumab and the small-molecules tyrosine-kinase inhibitors imatinib and (PLX4032) vemurafenib, clinical success of multiple other targeted drugs is modest. Breakthrough high-throughput-next-generation sequencing and latest arrays-based platforms change now research and rise rational optimism for clinical implementations. 1 As breast cancer and medulloblastoma are the most common malignant tumors in females and brain tumors in children, the first genomic studies applying these technologies in large number of clinical samples have more recently reported (Table 1) . Figure 1 delineates a current strategy to obtain deep-sequencing and transcriptomics data from clinical samples and correlates these genomic landscapes with clinical data, with purpose clinical biomarkers and novel therapeutics.
BREAST CANCER
Breast carcinoma is the leading cause of cancer-related mortality in women worldwide. The addition of targeted drugs, besides non-specific therapy, has substantially improved survival rates. Endocrine therapy with tamoxifen or aromatase inhibitors in premenopausal and postmenopausal estrogen receptor (ER)-positive patients, respectively, is standard treatment. Trastuzumab, an anti-HER2 antibody for (HER2) human epidermal growth factor type 2 receptor-positive women, added to chemotherapy improves overall survival in both adjuvant and metastatic setting. 2 Previous work with microarrays-based differentially expressed genes has provided promising data. However, despite the wide use of gene expression profiling-based molecular subtypes (luminal A, luminal B, HER2-enriched and basal-like) and gene expression signatures (70-gene, 21-gene assays) 1, 2 in research, their clinical utility remains controversial and awaits the results from underway phase 3-randomized trials. As cost drops, now breakthrough high-throughput genome-wide mapping technologies are being applied into clinical cancer genomebased potential for developing novel diagnostics and therapeutics. 1 More recently six genomics studies in relatively large number of clinical samples in patients with various breast cancer subtypes have been reported in Nature.
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DEEP-SEQUENCING AND INTEGRATIVE ANALYSIS OF CLINICAL SAMPLES
Stephens et al. 3 sequenced the exome (all the exons of proteincoding regions of the genome) by using whole-exome sequencing on 100 patients with breast cancer. Heterogeneity was the main finding with a 73% diversity rate of mutational landscapes. Of 40 cancer genes harboring somatic driver point mutations and/or copy number changes, each individual cancer had a maximum number of six mutated cancer genes involved in tumorigenesis.
Triple-negative breast cancer (TNBC) accounts for 10-20% of breast cancers with no expression of hormone receptor (ER, progesterone receptor) or HER2. In the absence of molecular characterization and activating signaling pathways, no targeted therapy exists. TNBC is an aggressive disease with resistance to cytotoxic chemotherapy and poor survival in some patients. Although arrays-based basal-like subtype corresponds to the TNBC, only 50-75% of TNBC matches the basal subtype.
Shah et al. 4 performed deep-sequencing and transcriptome analysis of cancer genomes in 104 primary TNBC tumors. They profiled the genomes with Affymetrix SNP 6.0 arrays (all cases), RNA-seq (80 cases; Illumina GAII), and whole-exome/genome sequencing (65 cases; tumor and normal DNA). They also found substantial genomic heterogeneity.
Banerji et al. 5 performed whole-exome sequencing on 103 tumor/normal pairs from breast cancer patients of diverse subtypes. They have discovered and report for the first time recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. In addition, the researchers performed whole-genome sequencing (WGS) in paired tumor/ normal from 22 patients and applied the dRanger algorithm to identify candidate genomic rearrangements. The recurrent translocation MAGI3-AKT3 in triple-negative breast cancer they found may have clinical implications: the genomic MAGI3-AKT3 fusion shows AKT3 as a potential therapeutic target.
Ellis et al. 6 report a WGS study in 46 cases in an effort to correlate mutations with phenotypes, clinical data and therapeutic breast cancer responsiveness. In 77 pretreatment tumor biopsies accrued from ER-positive breast cancer patients in two studies of neoadjuvant aromatase inhibitor therapy, 46 cases underwent WGS and 31 cases underwent whole-exome sequencing. The authors identified 18 significantly mutated genes, including CBFB and RUNX1 also involved in TNBC. 5 The authors suggest the need for new larger genome sequencing studies with statistical power to identify predictors of endocrine therapy response because of extreme heterogeneity in ER-positive subtype. 6 
INTEGRATIVE GENOMIC AND TRANSCRIPTOMIC ANALYSIS
Based on the critical role of copy number changes in gene expression regulation, Curtis et al. 7 looked at inherited copy number variants and acquired somatic copy number aberrations (CNAs). Using Affymetrix SNP 6.0 and Illumina high-throughput-12 v3 platforms for genomic and transcriptional profiling, respectively, of samples from 2000 breast cancer patients, the authors found that the total number of copy number changes was associated with expression in B40% of genes, among inherited copy number variants and SNPs and somatic CNAs. Interestingly, the researchers found that the landscape dominated by cis-and trans-acting CNAs. An analysis of paired DNA-RNA profiles revealed a high-risk, ER-positive 11q13/14 cis-acting subgroup and a favorable prognosis subgroup devoid of CNAs.
Moving from models to patient samples, Ross-Innes et al. 8 performed a transcriptome analysis using chromatin immunoprecipitation followed by WGS (chromatin immunoprecipitation-seq). This genome-wide mapping of ER-binding events in primary and metastatic frozen tissues samples from eight ER/progesterone receptor-positive patients was associated with distinct clinical outcomes. Therefore, chromatin immunoprecipitation-seq transcriptome analysis in clinical samples may provide exciting perspectives for identifying robust biomarkers for predicting response or resistance to endocrine therapy in ER-positive disease.
MEDULLOBLASTOMA
Medulloblastoma is an aggressively pediatric brain tumor. Four subgroups with distinct clinical, biological and genetic profiles include WNT, Sonic Hedgehog (SHH) and 3 and 4 subgroups, which are molecularly less well characterized. Multimodal treatment includes surgery, whole-brain radiation and aggressive chemotherapy but B40% of children recur and 30% die from their disease. Reduced quality of life is often occurred among survivors.
An integrative deep-sequencing analysis of 125 tumor-normal pairs was performed by Jones et al. 9 Beyond confirmation of recurrent mutations in known genes, the authors identified new medulloblastoma-related genes (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. With RNA-seq, the authors revealed the expression of the first medulloblastoma fusion genes. This study reveals the genomic complexity and heterogeneity underlying Medulloblastoma.
Northcott et al. 10 focused on the identification of somatic CNAs using GISTIC2 in 1087 medulloblastoma patients. The most common region of focal copy number gain was a tandem duplication of SNCAIP, a gene associated with Parkinson's disease. They found recurrent translocations PVT1-MYC and PVT1-NDRG1. For the clinic, crucial is the relation of alterations with signaling pathways. Northcott et al. 10 showed that the identified somatic CNAs are highly targetable, for specific subgroup and warrant exploration for future clinical trials including PI3K signaling in SHH, transforming growth factor beta (TGF-b) signaling in Group 3 and nuclear factor kappa-B signaling in Group 4. 10 
FUTURE PERSPECTIVES AND CONCLUSIONS
The dropping cost and the power of next-generation sequencing platforms to provide valid deep-sequencing data with WGS, whole-exome sequencing and RNA-seq in clinical samples in a short time has resulted in the new era of clinical cancer genome. 1 Genomic heterogeneity is a consisted finding from all reports in both the epithelial cells cancer and brain tumors. [3] [4] [5] [6] [7] [8] [9] [10] In addition to this patient-to-patient diversity, intratumor heterogeneity that requires additional sequencing of separate biopsies samples from the same tumor, further rises the challenges and emphasizes the need to reach personalized medicine at the clinical setting. To capture this genetic diversity, large number of patients and their samples should be sequenced and analyzed because most of the studies reported have been underpowered with small samples sizes. [2] [3] [4] [5] [6] 8, 9 In breast cancer, it appears that each individual tumor exhibits a nearly personal mutation landscape specific for each individual patient. All classes of genetic changes including point mutations, copy number variants/CNAs and translocations can be important for clinical diagnostics, biomarkers and therapeutics but the full repertoire of these genetic events has not been completed yet. However, even when such a complete database for each cancer type will emerge, it will be essential to link personal genomic landscape with gene expression data and pathways analysis to guide personalized therapeutic decisions. To predict disease phenotypes from genotype is much more complex approach than Ellis et al. 6 thought to perform WGS for predicting resistance or responsiveness to aromatase inhibitors treatment in ER-positive breast cancer. The genotype-phenotype relationship isn't a linear correlation but according to polygenic model the expression of multiple interacting genes guides the ultimate cellular behavior.
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Integrative deep-sequencing analysis of large number of samples is required for clinical implementation. Transcriptomic analysis in 2000 breast cancer patients by Curtis et al. 7 of paired DNA-RNA profiles revealed clinically important CNAs and two subgroups with prognostic significance. This finding warrants further evaluation in clinical trials. Similarly, in the analysis of somatic CNAs in B1000 medulloblastomas, Northcott et al. 10 report the identification of relevant and targetable somatic CNAs for the affected children.
The deep sequencing for point mutations, CNAs and translocations and transcriptome analysis [3] [4] [5] [6] [7] [8] [9] [10] confirm the heterogeneity and complexity of epithelial and brain tumors. As the network biology era just now begins, revealing the dynamics of genome architecture, 11 major challenges emerge in translating human genome analysis data into clinic. [11] [12] [13] [14] [15] An optimistic scenario suggests that creating a complete database of all classes of mutations including point mutations, copy number variants/CNAs and genomic translocations, then we could correlate these genotype data with gene expression and deregulated signaling pathways for improving response rates with appropriate combination of selected available drugs.
However, it is likely that to reach clinical success a comprehensive view of molecules, biological systems and their interactions beyond simple sequencing-based identification of genetic and epigenetic alterations will be required. These biological systems in living cells and organisms control gene expression, drive cellular signaling transduction through pathways networks and determine cell behavior. Now, breakthrough genome-wide mapping technologies and rapid advances in pathway analysis, 16 systems computational biology and mathematical network models shape the epoch of network biology. 11 Inheritance, personal lifestyle (diet, physical exercise) and environmental factors synthesize an extreme complex system, like ecosystem, with dynamic continuing interactions of molecules under environmental influence. 12 Without deeper insights into how driver mutations and epigenetic changes escape protective functional regulatory mechanisms leading in cancer, progress in biomedical science and health care will continue to be slow. 12 Deeper insights are required into how physical and functional networks of interacting DNA, non-coding RNAs including microRNAs, proteins and other molecules drive cells behavior in health and cancer states. Hopefully, step-by-step advances in transcriptome, proteome, epigenome and interactome analysis will lead to patients stratification and personalized health care through systems science-based integrative genome profile. [12] [13] [14] [15] [16] 
